Biomaterial Database

[A comparative trial of bronchodilator effects of fenoteral and sch 1000 in chronic bronchitis (author's transl)]. 1976

A Baronti, and A Grieco

In a group of 20 patients with chronic bronchitis, bronchodilator effects of fenoterol (400 mug), SCH 1000 (40 mug), and their combination (fenoterol 400 mug msch 1000 40 mug) have been evaluated and compared by measuring total pulmonary capacity (CPT), intrthoracic gas volume (VGT), forced expiratory volume in one second (VEMS), specific airways resistance (SRva) and maximun expiratory flow at a lung volume for which the initial flow was 0.1 l/s (Vo.iv). Measurements have been made before and 30, 60, 120 and 180 min after administration of the drug. With each of the three drugs, the improvement of the five functional parameters is statistically significant at all time intervals. Changes in CPT, VGT, VEMS and SRva are not statistically different when using the different drugs, whereas the Vo.1v changes suggest a lesser bronchodilator effect of SCH 1000 than fenoterol (p less than 0.05 at 180 min), and especially than fenoterol-SCH 1000 combination (p less than 0.05 at all time intervals). The combination is lightly but not significantly better than fenoterol only. On account of these results and the very high tolerance for the two drugs, a new medication combining SCH 1000 and fenoterol is desirable. The authors emphasize the sensitivity of maximum expiratory flow measurements at low lung volumes for trials on bronchodilators and the necessity to consider the possible reduction in CPT for flows comparison at an identical absolute lung volume.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008448	Maximal Expiratory Flow Rate	The airflow rate measured during the first liter expired after the first 200 ml have been exhausted during a FORCED VITAL CAPACITY determination. Common abbreviations are MEFR, FEF 200-1200, and FEF 0.2-1.2.	Forced Expiratory Flow 0.2-1.2,Forced Expiratory Flow 200-1200,Flow Rate, Maximal Expiratory,MEFR,Forced Expiratory Flow 0.2 1.2,Forced Expiratory Flow 200 1200
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D001991	Bronchitis	Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	Bronchitides
D001993	Bronchodilator Agents	Agents that cause an increase in the expansion of a bronchus or bronchial tubes.	Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002908	Chronic Disease	Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004338	Drug Combinations	Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.	Drug Combination,Combination, Drug,Combinations, Drug
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004983	Ethanolamines	AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives.	Aminoethanols